Vaxxinity Inc (PK:VAXX)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Apr 19, 2024 06:53 pm ET

Vaxxinity Issues Shareholder Letter

Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese...

Apr 19, 2024 04:27 pm ET

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to...

Mar 28, 2024 09:23 am ET

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual...

Mar 27, 2024 04:41 pm ET

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update....

Mar 07, 2024 10:32 am ET

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

Vaxxinity, Inc. (NASDAQ: VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from its UB-312 program in Parkinson’s disease (PD) presented by Jean-Cosme Dodart, PhD, SVP of Research at...

Feb 15, 2024 08:00 am ET

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density...

Feb 13, 2024 08:00 am ET

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its anti-tau program in...

Jan 30, 2024 08:00 am ET

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease...

Jan 18, 2024 08:00 am ET

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, funded by a grant...

Jan 03, 2024 08:00 am ET

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the 42nd Annual...

Nov 13, 2023 06:50 pm ET

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in...

Nov 08, 2023 08:30 am ET

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. “We continue to advance our...

Aug 29, 2023 08:00 am ET

Vaxxinity to Present at Upcoming Investor Conferences in September

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the following investor...

Aug 10, 2023 08:00 am ET

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the print publication of Phase 2a clinical trial data in The Lancet’s eBioMedicine (Volume 94, 104665, August 2023), stating that...

Aug 09, 2023 08:00 am ET

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. “Vaxxinity has broken new ground...

Jul 27, 2023 04:30 pm ET

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity’s leadership team as Executive Vice President, Global Scientific Director starting...

Jul 17, 2023 08:00 am ET

Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigational immunotherapeutic for...

Jun 22, 2023 08:00 am ET

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines today announced positive results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson’s disease (PD),...

May 09, 2023 08:00 am ET

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “Vaxxinity...

Mar 28, 2023 08:00 am ET

Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that members of its leadership team will present data on investigational vaccines for COVID-19 and...

Mar 27, 2023 07:50 am ET

Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates

Mar 21, 2023 08:00 am ET

Vaxxinity Joins TransCelerate Research and Development Consortium

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced today that it has joined TransCelerate BioPharma, Inc. (TransCelerate) as the first emerging biotechnology...

Mar 20, 2023 08:00 am ET

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial...

Mar 02, 2023 08:00 am ET

Vaxxinity to Present at Upcoming March Scientific and Medical Conferences

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that its scientists and executives will present at three upcoming scientific and medical conferences in March....

Feb 01, 2023 07:40 pm ET

Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced new appointments to the Board of Directors and the relocation of its corporate headquarters to Cape Canaveral, Fla....

Jan 05, 2023 08:00 am ET

Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at...

Dec 02, 2022 08:00 am ET

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced today that its next generation UB-612 COVID-19 vaccine, when administered as a single heterologous booster dose,...

Nov 10, 2022 07:30 am ET

Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the third quarter ended September 30, 2022. “The third quarter provided success in...

Nov 03, 2022 08:00 am ET

Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it will host its first in-person and virtual Analyst and R&D Day in New York on Thursday, November 10, 2022...

Nov 01, 2022 09:00 am ET

Vaxxinity to Present at Upcoming Investor Conferences in November

Oct 24, 2022 08:00 am ET

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that enrollment is complete for its global Phase 3 pivotal trial evaluating UB-612 as a heterologous booster...

Sep 13, 2022 08:00 am ET

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin...

Sep 12, 2022 08:00 am ET

Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it has initiated a rolling submission to the Medicines and Healthcare products Regulatory Agency (MHRA) in...

Sep 01, 2022 08:00 am ET

Vaxxinity to Present at Upcoming Investor Conferences in September

Aug 11, 2022 08:00 am ET

Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the second quarter ended June 30, 2022. “We continue to advance our vaccine candidates...

Aug 04, 2022 07:00 am ET

Vaxxinity to Present at the Canaccord Genuity 42nd Annual Growth Conference

Aug 02, 2022 08:00 am ET

Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in non-human primates and the...

Aug 01, 2022 08:00 am ET

Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC)

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD)...

Jul 25, 2022 11:57 am ET

Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines

Vaxxinity, Inc. (Nasdaq: VAXX) Chief Executive Officer Mei Mei Hu will participate as a speaker at the White House Summit on the Future of COVID-19 Vaccines. Hu is honored by the invitation and eager to engage in discussion on the critical...

Jun 02, 2022 10:35 am ET

Thinking about buying stock in Borr Drilling, FuelCell Energy, Vaxxinity, Marathon Oil, or View?

NEW YORK, June 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BORR, FCEL, VAXX, MRO, and VIEW.

Jun 02, 2022 07:00 am ET

Vaxxinity to Participate at the Jefferies Healthcare Conference

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will participate in a fireside chat at the...

May 12, 2022 09:31 am ET

Thinking about buying stock in Squarespace, Cullinan Oncology, Moneylion, SmartRent, or Vaxxinity?

NEW YORK, May 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SQSP, CGEM, ML, SMRT, and VAXX.

May 09, 2022 07:42 am ET

Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates

May 05, 2022 07:00 am ET

Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference

May 02, 2022 09:31 am ET

Thinking about buying stock in Cyngn, Redbox Entertainment, Veru, Highpeak Energy, or Vaxxinity?

NEW YORK, May 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CYN, RDBX, VERU, HPK, and VAXX.

May 02, 2022 08:00 am ET

Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease

Vaxxinity, Inc. (Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. Food...

Apr 28, 2022 08:00 am ET

Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson’s...

Apr 06, 2022 04:43 pm ET

CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global pivotal...

Mar 28, 2022 08:00 am ET

Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it has begun dosing participants in a Phase 3 pivotal trial of UB-612, the Company’s next-generation...

Mar 24, 2022 04:05 pm ET

Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates

Mar 21, 2022 07:00 am ET

Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as...

Feb 11, 2022 09:28 am ET

Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Investigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at levels similar to or higher than approved vaccinesUB-612 elicits >- Vaxxinity, Inc. (Nasdaq:...

Jan 12, 2022 09:21 am ET

Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first patient with Parkinson’s disease (PD) has been dosed with UB-312 in Part B of a double-blinded,...

Jan 10, 2022 07:00 am ET

Vaxxinity Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Support UB-312 Vaccine Study

Vaxxinity, Inc. (NASDAQ: VAXX), a clinical-stage biotech company pioneering a new class of immunotherapeutic vaccines to treat and prevent chronic neurological diseases, including Alzheimer’s and Parkinson’s, has announced that the company has been...

Jan 04, 2022 07:00 am ET

Vaxxinity Appoints Jason Pesile as SVP, Finance & Accounting, and George Hornig to Board of Directors

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the appointment of Jason Pesile, MBA, CPA, as Senior Vice President, Finance & Accounting. The Company also...

Dec 23, 2021 04:45 pm ET

Vaxxinity Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

Nov 18, 2021 04:05 pm ET

Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters’ Option to Purchase Additional Shares

Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the closing of its initial public offering of 6,000,000 shares of class A common stock at a public offering price...

Nov 11, 2021 06:30 am ET

Vaxxinity Announces Pricing of Initial Public Offering

Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the pricing of its initial public offering of 6,000,000 shares of class A common stock at a public offering price...

Ad blocking detected

Vaxxinity Inc (PK:VAXX)

Business Focus: Biotechnology & Medical Research